in this issue
Regions :: North America :: U.S.
Hospira completes acquisition of Orchid's API manufacturing and R&D facilities in India for $218 million
8:40 PM MDT | July 4, 2014 | Deepti Ramesh
Hospira (Lake Forest, IL), the world's leading provider of injectable drugs and infusion technologies, announced on 4 July that it has completed the previously announced acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals (Chennai, India), a leading Indian pharmaceuticals company, for about $218 million. The API manufacturing facility is located at Aurangabad, India and the associated R&D facility is located at Chennai. Plans...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be: